| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Ab169270-100μg |
100μg |
现货  |
| |
| Ab169270-1mg |
1mg |
现货 |
| |
| Ab169270-5mg |
5mg |
现货 |
| |
| Ab169270-10mg |
10mg |
期货 |
|
| 产品名称 | Vedolizumab (anti-α4β7-integrin), 整合素 α4β7 抗体 |
|---|---|
| 别名 | 维多珠单抗 | Anti-Human lymphocyte α4β7 integrin, Humanized Antibody | Vedolizumab (anti-α4β7-integrin) | 维多珠单抗(抗α4β7整合素) |
| 英文别名 | Recombinant Vedolizumab Antibody | Vedolizumab | Entyvio | Anti-Integrin a4b7 (ITGA4 & ITGB7) Reference Antibody (vedolizumab) | Antigen CD49D antibody | CD49d antibody | IA4 antibody | Integrin alpha 4 subunit antibody | Integrin alpha IV antibody | Inte |
| 规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
| 宿主种属 | 人(Human) |
| 特异性 | Integrin a4b7 (ITGA4 & ITGB7) |
| 应用 | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| 种属反应性 | 人(Human) |
| 偶联 | Unconjugated |
| 作用类型 | 抑制剂 |
| 作用机制 | 整合素 α4β7 抗体 |
| 抗体类型 | Primary antibody |
|---|---|
| 克隆类型 | 重组抗体 |
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | kappa |
| SDS-PAGE | 26.5 kDa (Light Chain) & 50.8 kDa (Heavy Chain), under reducing conditions; 178.5 kDa, under non-reducing conditions. |
| 纯化方法 | Protein A purified |
| 纯度 | >95% |
| 来源 | CHO supernatant |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| CAS编号和信息 | 943609-66-3 |
| 分子类型 | 抗体 |
Vedolizumab (anti-α4β7-integrin) (Ab169270) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling α4β7-integrin (red) with Vedolizumab (anti-α4β7-integrin) (Ab169270). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (
Ab170213
). Black - Unlabelled control, cells without incubation with primary antibody.
Vedolizumab (anti-α4β7-integrin) (Ab169270) - SEC
The purity of Vedolizumab (anti-α4β7-integrin) (Ab169270) is more than 95% verified by HPLC.
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！
| 批号(Lot Number) | 证书类型 | 日期 | 货号 |
|---|---|---|---|
 ZJ24F0911275 |
分析证书 | 24-09-27 | Ab169270 |
| ZJ24F0911277 |
分析证书 | 24-09-27 | Ab169270 |
| ZJ24F0911276 |
分析证书 | 24-09-27 | Ab169270 |
| ZJ23F0800947 |
分析证书 | 23-08-30 | Ab169270 |
| 1. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. (2009) The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.. J Pharmacol Exp Ther, 330 (3): (864-75). [PMID:19509315] |
首页
400-620-6333
